Cargando…
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial
Sunitinib is the most commonly prescribed drug for advanced renal cell carcinoma in the first-line setting and has been associated with multiple adverse events related to its on–and off–target effects, including hand and foot syndrome and fatigue. It was hypothesized that sunitinib-induced fatigue m...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864863/ https://www.ncbi.nlm.nih.gov/pubmed/29615901 http://dx.doi.org/10.3389/fphar.2018.00189 |
_version_ | 1783308572865593344 |
---|---|
author | Buonerba, Carlo De Placido, Pietro Bruzzese, Dario Pagliuca, Martina Ungaro, Paola Bosso, Davide Ribera, Dario Iaccarino, Simona Scafuri, Luca Liotti, Antonietta Romeo, Valeria Izzo, Michela Perri, Francesco Casale, Beniamino Grimaldi, Giuseppe Vitrone, Francesca Brunetti, Arturo Terracciano, Daniela Marinelli, Alfredo De Placido, Sabino Di Lorenzo, Giuseppe |
author_facet | Buonerba, Carlo De Placido, Pietro Bruzzese, Dario Pagliuca, Martina Ungaro, Paola Bosso, Davide Ribera, Dario Iaccarino, Simona Scafuri, Luca Liotti, Antonietta Romeo, Valeria Izzo, Michela Perri, Francesco Casale, Beniamino Grimaldi, Giuseppe Vitrone, Francesca Brunetti, Arturo Terracciano, Daniela Marinelli, Alfredo De Placido, Sabino Di Lorenzo, Giuseppe |
author_sort | Buonerba, Carlo |
collection | PubMed |
description | Sunitinib is the most commonly prescribed drug for advanced renal cell carcinoma in the first-line setting and has been associated with multiple adverse events related to its on–and off–target effects, including hand and foot syndrome and fatigue. It was hypothesized that sunitinib-induced fatigue may be related to off target inhibition of the AMPK enzyme, which results in impairment of energy-producing processes at a systemic level. Quercetin is a naturally occurring flavonol with established AMPK-stimulating activity. While clinical use of quercetin is limited by its poor bio-availability, quercetin-3-O-β-d-glucopyranoside, that is isoquercetin, has an improved pharmacokinetic profile. On the grounds of the in vitro stimulatory activity with respect to AMPk, we hypothesized that oral isoquercetin could improve fatigue in kidney cancer patients receiving sunitinib. Given the lack of data on the safety of isoquercetin given concomitantly with sunitinib, we conducted a phase I trial to assess the safety of GMP manufactured isoquercetin given at two dose levels (450 and 900 mg a day). In the 12-patient study cohort included in this study, isoquercetin was administered concomitantly with 50 mg sunitinib for a median 81 days (IQR, 75.5, 86.5). None of the 12 patients required isoquercetin suspension or isoquercetin dose reduction because of adverse events. No abnormalities in ECG, heart or lower limbs doppler ultrasound were detected. A statistically significant improvement was reported for the FACIT fatigue score (6.8 points; 95% CI: 2.8–10.8; p = 0.002) and for the FACIT Adverse Events score (18.9 points; 95% CI: 9.1–28.8; p < 0.001) after isoquercetin consumption vs. baseline. In this phase I trial, isoquercetin was remarkably safe, with a preliminary signal of activity in terms of improvement of sunitinib adverse events. |
format | Online Article Text |
id | pubmed-5864863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58648632018-04-03 Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial Buonerba, Carlo De Placido, Pietro Bruzzese, Dario Pagliuca, Martina Ungaro, Paola Bosso, Davide Ribera, Dario Iaccarino, Simona Scafuri, Luca Liotti, Antonietta Romeo, Valeria Izzo, Michela Perri, Francesco Casale, Beniamino Grimaldi, Giuseppe Vitrone, Francesca Brunetti, Arturo Terracciano, Daniela Marinelli, Alfredo De Placido, Sabino Di Lorenzo, Giuseppe Front Pharmacol Pharmacology Sunitinib is the most commonly prescribed drug for advanced renal cell carcinoma in the first-line setting and has been associated with multiple adverse events related to its on–and off–target effects, including hand and foot syndrome and fatigue. It was hypothesized that sunitinib-induced fatigue may be related to off target inhibition of the AMPK enzyme, which results in impairment of energy-producing processes at a systemic level. Quercetin is a naturally occurring flavonol with established AMPK-stimulating activity. While clinical use of quercetin is limited by its poor bio-availability, quercetin-3-O-β-d-glucopyranoside, that is isoquercetin, has an improved pharmacokinetic profile. On the grounds of the in vitro stimulatory activity with respect to AMPk, we hypothesized that oral isoquercetin could improve fatigue in kidney cancer patients receiving sunitinib. Given the lack of data on the safety of isoquercetin given concomitantly with sunitinib, we conducted a phase I trial to assess the safety of GMP manufactured isoquercetin given at two dose levels (450 and 900 mg a day). In the 12-patient study cohort included in this study, isoquercetin was administered concomitantly with 50 mg sunitinib for a median 81 days (IQR, 75.5, 86.5). None of the 12 patients required isoquercetin suspension or isoquercetin dose reduction because of adverse events. No abnormalities in ECG, heart or lower limbs doppler ultrasound were detected. A statistically significant improvement was reported for the FACIT fatigue score (6.8 points; 95% CI: 2.8–10.8; p = 0.002) and for the FACIT Adverse Events score (18.9 points; 95% CI: 9.1–28.8; p < 0.001) after isoquercetin consumption vs. baseline. In this phase I trial, isoquercetin was remarkably safe, with a preliminary signal of activity in terms of improvement of sunitinib adverse events. Frontiers Media S.A. 2018-03-16 /pmc/articles/PMC5864863/ /pubmed/29615901 http://dx.doi.org/10.3389/fphar.2018.00189 Text en Copyright © 2018 Buonerba, De Placido, Bruzzese, Pagliuca, Ungaro, Bosso, Ribera, Iaccarino, Scafuri, Liotti, Romeo, Izzo, Perri, Casale, Grimaldi, Vitrone, Brunetti, Terracciano, Marinelli, De Placido and Di Lorenzo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Buonerba, Carlo De Placido, Pietro Bruzzese, Dario Pagliuca, Martina Ungaro, Paola Bosso, Davide Ribera, Dario Iaccarino, Simona Scafuri, Luca Liotti, Antonietta Romeo, Valeria Izzo, Michela Perri, Francesco Casale, Beniamino Grimaldi, Giuseppe Vitrone, Francesca Brunetti, Arturo Terracciano, Daniela Marinelli, Alfredo De Placido, Sabino Di Lorenzo, Giuseppe Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial |
title | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial |
title_full | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial |
title_fullStr | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial |
title_full_unstemmed | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial |
title_short | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial |
title_sort | isoquercetin as an adjunct therapy in patients with kidney cancer receiving first-line sunitinib (quasar): results of a phase i trial |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864863/ https://www.ncbi.nlm.nih.gov/pubmed/29615901 http://dx.doi.org/10.3389/fphar.2018.00189 |
work_keys_str_mv | AT buonerbacarlo isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT deplacidopietro isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT bruzzesedario isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT pagliucamartina isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT ungaropaola isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT bossodavide isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT riberadario isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT iaccarinosimona isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT scafuriluca isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT liottiantonietta isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT romeovaleria isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT izzomichela isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT perrifrancesco isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT casalebeniamino isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT grimaldigiuseppe isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT vitronefrancesca isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT brunettiarturo isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT terraccianodaniela isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT marinellialfredo isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT deplacidosabino isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial AT dilorenzogiuseppe isoquercetinasanadjuncttherapyinpatientswithkidneycancerreceivingfirstlinesunitinibquasarresultsofaphaseitrial |